Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients

doi:10.1016/0006-3223(93)90288-o

PMID: 8097114DOI: 10.1016/0006-3223(93)90288-oFeb 15, 1993

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients

Biological Psychiatry

A L NordströmG Uppfeldt

Abstract

The relationship between central D2-dopamine receptor occupancy and antipsychotic drug effects was examined in a double-blind study. Raclopride was the compound used to induce a selective occupancy of the D2-dopamine receptors. In addition, 11C-labeled raclopride was the radioligand used to measure occupancy by positron emission tomography (PET). Seventeen schizophrenic patients were randomly assigned to one of three parallel groups treated for 4 weeks with daily doses of 2, 6, or 12 mg of raclopride. D2-receptor occupancy was determined by PET at steady-state conditions in 13 patients who completed the study. A statistically significant relationship was demonstrated between antipsychotic effect and degree of D2-receptor occupancy (p < 0.05). Patients with extrapyramidal side effects had significantly higher D2-receptor occupancy than those without (p = 0.02). The finding of a relationship between selective occupancy of the D2-dopamine receptors and clinical effects in schizophrenic patients principally provides new support for the dopamine hypothesis of antipsychotic drug action.

References

Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

Apr 30, 1976·Science·I CreeseS H Snyder

Antipsychotic drugs, neurotransmitters, and schizophrenia

Feb 1, 1978·The American Journal of Psychiatry·A Carlsson

Antipsychotic drug doses and neuroleptic/dopamine receptors

Jun 24, 1976·Nature·Philip SeemanK Wong

Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol

Jan 1, 1992·Psychopharmacology·A L NordströmChrister Halldin

Dopamine in schizophrenia: a review and reconceptualization

Nov 1, 1991·The American Journal of Psychiatry·K L DavisM Davidson

A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding

Jan 1, 1991·International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology·Christer HalldinO Solin

D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride

Mar 1, 1990·Archives of General Psychiatry·Lars FardeG Sedvall

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

Sep 13, 1990·Nature·P SokoloffJ C Schwartz

Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage

Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·Philip Seeman

Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET

Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·Lars Farde, C von Bahr

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial

Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·Y D LapierreR Manchanda

Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride

Dec 1, 1990·Archives of General Psychiatry·Philip SeemanH C Guan

Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels

Jan 1, 1989·Psychopharmacology·J C BaronB Mazière

A rating scale for drug-induced akathisia

May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes

Repeated haloperidol administration changes basal release of striatal dopamine and subsequent response to haloperidol challenge

Apr 10, 1989·Brain Research·W ZhangJ S Hong

Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET

Jan 17, 1986·Science·Lars FardeG Sedvall

Plasma level monitoring of antipsychotic drugs. Clinical utility

Jan 1, 1986·Clinical Pharmacokinetics·S G Dahl

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs

Jan 1, 1988·Archives of General Psychiatry·Lars FardeG Sedvall

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

Jan 1, 1988·Archives of General Psychiatry·R J BaldessariniM H Teicher

In vivo assay for neuroleptic receptor binding in the striatum. Positron tomography in humans

Dec 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·H CambonB Mazière

The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions

Jan 1, 1986·Psychopharmacology·S O OgrenS E Sjöstrand

Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients

Apr 1, 1988·Biological Psychiatry·M SmithA Wolkin

An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET

Jan 1, 1988·Psychopharmacology·Lars FardeG Sedvall

Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography

Jun 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·Lars FardeG Sedvall

Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain

Jul 1, 1985·Biochemical Pharmacology·C KöhlerL Gawell

Observations of placebo response in chronic schizophrenic patients

May 1, 1966·Archives of General Psychiatry·M P Bishop, D M Gallant

Important issues in the drug treatment of schizophrenia

Jan 1, 1980·Schizophrenia Bulletin·J M DavisC Chan

Performance study of the PC-384 positron camera system for emission tomography of the brain

Feb 1, 1984·Journal of Computer Assisted Tomography·J LittonM Kesselberg

Head fixation device for reproducible position alignment in transmission CT and positron emission tomography

Feb 1, 1981·Journal of Computer Assisted Tomography·M BergströmL Widén

Determination of object contour from projections for attenuation correction in cranial positron emission tomography

Apr 1, 1982·Journal of Computer Assisted Tomography·M BergströmG Blomqvist

High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET

Jan 1, 1993·Psychopharmacology·A L NordströmChrister Halldin

Citations

The future of imaging in drug discovery

Aug 6, 1999·Journal of Clinical Pharmacology·M E Schmidt

D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status

Jan 1, 1995·Journal of Neural Transmission. General Section·R Schlösser, S Schlegel

Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS)

Jan 1, 1995·Journal of Neural Transmission. General Section·J StaedtE Rüther

The modulation of brain dopamine and GABAA receptors by estradiol: a clue for CNS changes occurring at menopause

Apr 1, 1996·Cellular and Molecular Neurobiology·R Bossé, T DiPaolo

Review: treatment of schizophrenia. State of the art

Jan 1, 1996·European Archives of Psychiatry and Clinical Neuroscience·H J Möller

Influence of rate of administration of raclopride on akathisia and prolactin response

Mar 1, 1994·Psychopharmacology·G Movin-OsswaldLars Farde

5-HT2 antagonism and EPS benefits: is there a causal connection?

Mar 1, 1996·Psychopharmacology·S Kapur

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study

Mar 1, 1996·Psychopharmacology·Lyn S PilowskyR W Kerwin

In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia

Mar 1, 1996·Psychopharmacology·J L MartinotB Mazière

A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration

Mar 10, 2004·Psychopharmacology·Mirjam TalvikLars Farde

Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients

Mar 5, 2004·Psychopharmacology·Rodrigo A BressanLyn S Pilowsky

The potential role of lamotrigine in schizophrenia

Jul 8, 2005·Psychopharmacology·Charles H LargeDonald C Goff

Differential effects of clozapine and haloperidol on interval timing in the supraseconds range

Jul 8, 2005·Psychopharmacology·Christopher J MacDonald, Warren H Meck

A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian)

Jun 11, 2005·Psychopharmacology·Y HodéJ P Macher

Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects

Jun 8, 2006·Psychopharmacology·R CoccurelloA Moles

Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol

Nov 18, 2006·Psychopharmacology·M ReimoldH Wormstall

Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia

Dec 7, 2007·Psychopharmacology·Ryosuke ArakawaTetsuya Suhara

Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects

Mar 30, 2010·Psychopharmacology·Ryosuke ArakawaTetsuya Suhara

Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine

Jul 9, 2010·Psychopharmacology·Hans RasmussenBirte Glenthoj

Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers

Jun 7, 2011·Psychopharmacology·Tanja VeselinovicGerhard Gründer

Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457

Jan 13, 2012·Psychopharmacology·Keisuke TakahataTetsuya Suhara

Effects of amisulpride on human resting cerebral perfusion

Apr 16, 2013·Psychopharmacology·Roberto VivianiBirgit Abler

Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry

Jan 16, 2008·European Journal of Clinical Pharmacology·Christoph Hiemke

Risperidone augmentation of clozapine: a critical review

Aug 11, 2006·European Archives of Psychiatry and Clinical Neuroscience·Vassilis P KontaxakisG N Christodoulou

Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

Apr 12, 2008·European Archives of Psychiatry and Clinical Neuroscience·Christoph Hiemke

Extrastriatal dopamine D(2) receptor occupancy in olanzapine-treated patients with schizophrenia

Oct 24, 2009·European Archives of Psychiatry and Clinical Neuroscience·Ryosuke ArakawaTetsuya Suhara

Modeling of PET data in CNS drug discovery and development

May 11, 2013·Journal of Pharmacokinetics and Pharmacodynamics·Katarina VarnäsLars Farde

Dopamine hypothesis of schizophrenia: making sense of it all

Sep 21, 2007·Current Psychiatry Reports·Mitsuru Toda, Anissa Abi-Dargham

The effects of raclopride on vacuous jaw movements in rats following acute administration

Jul 1, 1996·Physiology & Behavior·R E SteinpreisA Harrington

Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats

May 1, 1996·Neuroscience·R E SeeB A Sorg

Effect of clozapine and risperidone on 5-HT2 and D2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study

Mar 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·H HallG Sedvall

PET imaging of neuroreceptors in schizophrenia

Jan 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·G SedvallChrister Halldin

Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate

Jan 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A C AltamuraM Maes

Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens

Mar 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M M MarcusT Svensson

Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients

Oct 7, 1996·Psychiatry Research·S NybergChrister Halldin

How antipsychotics work-from receptors to reality

Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·S KapurMing Li

Half a century of antipsychotics and still a central role for dopamine D2 receptors

Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·S Kapur, David C Mamo

Serotonin receptors: their key role in drugs to treat schizophrenia

Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Herbert Y MeltzerJunji Ichikawa

How antipsychotics work: the patients' perspective

May 24, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Romina MizrahiS Kapur

New genetic insights highlight 'old' ideas on motor dysfunction in dystonia

Oct 23, 2013·Trends in Neurosciences·Rose E GoodchildAntonio Pisani

Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient

Nov 3, 1998·Biological Psychiatry·J M MeyerG Simpson

Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain?

Nov 16, 2002·European Journal of Pharmacology·Ben H C Westerink

alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs

Feb 20, 2003·European Journal of Pharmacology·Hans O Kalkman, Erika Loetscher

Nuclear medicine in neurology and psychiatry

Oct 6, 1999·Lancet·D C CostaP J Ell

Schizophrenia: from phenomenology to neurobiology

Jun 6, 2003·Neuroscience and Biobehavioral Reviews·Albert Hung Choy Wong, Hubert H M Van Tol

An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol

Jan 30, 1999·Psychiatry Research·J Zhang-WongG Bean

In vivo monitoring of drugs using radiotracer techniques

Mar 4, 2000·Advanced Drug Delivery Reviews·A SaleemP M Price

Dose-response relationships for the antipsychotic effects and Parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications

Jan 9, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·R Miller

Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine

Jun 27, 2002·Schizophrenia Research·M MarkianosG N Christodoulou

The Dose Reduction in Schizophrenia (DORIS) Study: a final report

Jan 17, 1997·Schizophrenia Research·J HirschowitzC Curtis

The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development

Dec 7, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Peter S Talbot, Marc Laruelle

Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat

Nov 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M L WadenbergS Ahlenius

Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint

Sep 1, 2001·Psychiatry Research·M BernardoM Salamero

Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels

Nov 14, 1997·Psychiatry Research·Michael B KnableD R Weinberger

In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine

Sep 11, 1999·Psychiatry Research·Thomas J RaedlerD R Weinberger

Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach

Jan 12, 2002·Nuclear Medicine and Biology·Stefano ZamunerAlan Bye

Schizophrenia and antipsychotic somatic treatment

Oct 1, 1996·International Journal of Technology Assessment in Health Care·Leif Lindström, I M Wieselgren

PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects

Dec 4, 2002·Acta Neurologica Scandinavica·B GulyásLars Farde

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

Oct 9, 2002·Acta Psychiatrica Scandinavica·O Freudenreich, D C Goff

Dopamine D2 receptor blockade reduces response likelihood but does not affect latency to emit a learned sensory-motor response: implications for Parkinson's disease

Nov 21, 2000·Behavioral Neuroscience·J C Horvitz, Y S Eyny

Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride

Apr 18, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·L S KegelesAnissa Abi-Dargham

The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro

Apr 23, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Patrick N McCormickAlan A Wilson

The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys

Mar 10, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karl-Anton Dorph-PetersenDavid A Lewis

Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia

Nov 2, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ofer AgidS Kapur

D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia

Apr 20, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David C MamoDavid McDonnell

Long-acting antipsychotic medication, restraint and treatment in the management of acute psychosis

Nov 2, 1999·The Australian and New Zealand Journal of Psychiatry·P Fitzgerald

Differential effects of typical and atypical antipsychotic drugs on striosome and matrix compartments of the striatum

Mar 12, 2002·The European Journal of Neuroscience·Michael Bubser, Ariel Y Deutch

Applications of positron emission tomography in psychiatry

May 21, 2003·Seminars in Nuclear Medicine·Ramin V Parsey, J John Mann

Schizophrenia

Jan 4, 1996·The New England Journal of Medicine·J M Kane

Prominence of the dopamine D2 short isoform in dopaminergic pathways

Jun 24, 1998·Proceedings of the National Academy of Sciences of the United States of America·Z U KhanP S Goldman-Rakic

Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol

Jun 15, 2007·Cognitive Neuropsychiatry·Luc J BoulayRobert Milin

Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature

Feb 28, 2008·Schizophrenia Bulletin·James M StoneLyn S Pilowsky

The dopamine hypothesis of schizophrenia: version III--the final common pathway

Mar 28, 2009·Schizophrenia Bulletin·Oliver D Howes, S Kapur

Presynaptic regulation of dopamine transmission in schizophrenia

Jun 16, 2009·Schizophrenia Bulletin·Gholson J LyonDavid Sulzer

High-dose olanzapine for treatment-refractory schizophrenia

Apr 3, 2003·Clinical Neuropharmacology·Vladimir Lerner

Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia

Mar 7, 2006·Clinical Neuropharmacology·Fayçal MouaffakDavid Gourion

In vivo kinetics of [18F](N-methyl)benperidol: a novel PET tracer for assessment of dopaminergic D2-like receptor binding

Aug 1, 1997·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·S M MoerleinM J Welch

Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding

Sep 18, 1998·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·H ItoLars Farde

Probing targets for antipsychotic drug action with PET and SPET receptor imaging

Jul 17, 2001·Nuclear Medicine Communications·Lyn S Pilowsky

Relation between cortical dopamine D(2) receptor occupancy and suppression of conditioned avoidance response in non-human primate

May 20, 2004·Psychiatry and Clinical Neurosciences·Akihiro TakanoS Kapur

Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine

Jun 6, 2009·Psychiatry and Clinical Neurosciences·Heli TuppurainenJari Tiihonen

Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography

Sep 1, 1995·British Journal of Pharmacology·K YanaiM Itoh

Motor and mental aspects of acute extrapyramidal syndromes

Jan 1, 1994·Acta Psychiatrica Scandinavica. Supplementum·D E Casey

Effects of intermittent and continuous subchronic administration of raclopride on motor activity, dopamine turnover and receptor occupancy in the rat

Dec 1, 1996·Pharmacology & Toxicology·H EricsonB Mohringe

Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone

Jan 5, 2012·The Journal of Pharmacology and Experimental Therapeutics·E C MulyL L Howell

mRNA transcript diversity creates new opportunities for pharmacological intervention

Feb 10, 2012·Molecular Pharmacology·Elizabeth S BarrieWolfgang Sadee

Translating glutamate: from pathophysiology to treatment

Oct 1, 2011·Science Translational Medicine·D C JavittChi-Ming Lee

No change in dopamine D1 receptor in vivo binding in rats after sub-chronic haloperidol treatment

Mar 26, 2002·Canadian Journal of Physiology and Pharmacology·Vito SanciJean N DaSilva

Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients

Nov 13, 2004·Neuropsychobiology·Matthias VogelIngolf Cascorbi

Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns

Apr 28, 2004·BMC Psychiatry·Rogelio ApiquianHumberto Nicolini

Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance

Aug 21, 2012·PloS One·Elodie M GiraultAndries Kalsbeek

Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response

Dec 20, 2012·PloS One·Hugo GeertsAnthony A Grace

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders

Nov 16, 2012·Neuropsychiatric Disease and Treatment·Nizar El-Khalili

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone

Jun 27, 2009·Neuropsychiatric Disease and Treatment·Hong Liu-SeifertJan Volavka

Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic

Feb 1, 2007·Neuropsychiatric Disease and Treatment·Pierre Chue

Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives

Jul 31, 2007·Drugs·Hans-Jürgen Möller

Pharmacogenetics of olanzapine metabolism

Aug 13, 2013·Pharmacogenomics·Mao Mao Söderberg, Marja-Liisa Dahl

D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder

Oct 1, 2013·CNS Spectrums·Steven G PotkinAdrian Preda

Dopaminergic basis of salience dysregulation in psychosis

Jan 7, 2014·Trends in Neurosciences·Toby T Winton-BrownOliver D Howes

Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms

Dec 25, 2010·The AAPS Journal·Rik de GreefJohn Panagides

Presynaptic dopaminergic function: implications for understanding treatment response in psychosis

Jun 13, 2014·CNS Drugs·I Bonoldi, Oliver D Howes

Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach

May 6, 2014·Pharmaceutical Research·Martin JohnsonJohannes H Proost

A national survey of the management of delirium in UK intensive care units

Feb 9, 2010·QJM : Monthly Journal of the Association of Physicians·R Mac SweeneyIntensive Care Foundation

Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism

Feb 15, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Georges VauquelinPhilip Seeman

Practical Guidance for Dosing and Switching from Paliperidone Palmitate 1-Monthly to 3-Monthly Formulation in Schizophrenia

Aug 27, 2015·Current Medical Research and Opinion·S GopalMahesh N Samtani

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

Dec 17, 2009·Current Medical Research and Opinion·S GopalL Alphs

Potential of Oxytocin in the Treatment of Schizophrenia

Feb 20, 2016·CNS Drugs·Paul D Shilling, David Feifel

Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring

Jul 4, 2009·Acta Psychiatrica Scandinavica·A SparshattS Kapur

A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia

Apr 3, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mark E SchmidtLuc Van Nueten

Delirium prevention and treatment

Nov 15, 2011·Anesthesiology Clinics·Yoanna Skrobik

Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy

Jan 1, 2016·Pharmaceutical Research·Martin JohnsonJohannes H Proost

Measurement of dopamine D2 receptors in living human brain using [11C]raclopride with ultra-high specific radioactivity

Sep 28, 2010·Nuclear Medicine and Biology·Yota FujimuraTetsuya Suhara

Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine

Feb 24, 2010·Journal of Psychiatric Research·Georg NikischAndreas Hertel

Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment

Dec 8, 2009·Journal of Psychiatric Research·Ina GieglingAlessandro Serretti

Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia

Mar 10, 2009·Pharmacology & Therapeutics·Jared W YoungMark A Geyer

Target site occupancy: emerging generalizations from clinical and preclinical studies

Mar 25, 2009·Pharmacology & Therapeutics·Sarah Grimwood, Paul R Hartig

Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area

Jul 2, 2008·Life Sciences·Lilly SchwielerGöran Engberg

Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting

Dec 19, 2007·Journal of Psychiatric Research·Malin AleniusMargareta Hammarlund-Udenaes

In vitro binding of [(11)C]raclopride with ultrahigh specific activity in rat brain determined by homogenate assay and autoradiography

Dec 27, 2007·Nuclear Medicine and Biology·Junko NoguchiKazutoshi Suzuki

From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission

Apr 17, 2007·Brain Research Reviews·Kjell FuxeLuigi F Agnati

The role of dopamine in reward and pleasure behaviour--review of data from preclinical research

May 10, 2005·Acta Psychiatrica Scandinavica. Supplementum·Rodrigo A Bressan, J A Crippa

High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies

Jan 10, 2009·British Journal of Clinical Pharmacology·Kang SimNorman Sartorius

Application of feedback-controlled bolus plus infusion (FC-B/I) method for quantitative PET imaging of dopamine transporters with [(18)F]β-CFT-FE in conscious monkey brain

Oct 9, 2012·Synapse·Norihiro HaradaHideo Tsukada

Antipsychotic occupancy of dopamine receptors in schizophrenia

Dec 15, 2010·CNS Neuroscience & Therapeutics·Magdalena Nord, Lars Farde

Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol

Dec 22, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·I CorripioEnric Alvarez

Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies

Jan 12, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Anissa Abi-Dargham, Marc Laruelle

Optimal experiment design for PET quantification of receptor concentration

Jan 1, 1996·IEEE Transactions on Medical Imaging·R R MuzicF Miraldi

D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment

May 16, 1998·Biological Psychiatry·J SchröderH Sauer

Evaluation of semi-quantitative method for quantification of dopamine transporter in human PET study with ¹⁸F-FE-PE2I

Jul 3, 2015·Annals of Nuclear Medicine·Yoko IkomaHiroshi Ito

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

Dec 18, 2001·Biological Psychiatry·S Kapur, Gary Remington

Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials

Aug 15, 2006·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Petros SkapinakisVenetsanos Mavreas

Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable

Dec 6, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rossella MedoriGerhard Gründer

Limbic selectivity of clozapine

Aug 16, 1997·Lancet·Lyn S PilowskyR W Kerwin

Early treatment response predicted subsequent clinical response in patients with schizophrenia taking paliperidone extended-release

Sep 1, 2015·Psychiatry Research·En-Chi YehChih-Chiang Chiu

Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen

Jan 5, 2006·British Journal of Clinical Pharmacology·Manabu TashiroKazuhiko Yanai

Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication

Jun 16, 2006·Acta Psychiatrica Scandinavica·R NesvågL Tanum

Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics

Jun 25, 2009·Human Psychopharmacology·William V BoboHerbert Y Meltzer

Cariprazine for the Treatment of Bipolar Disorder

Apr 10, 2016·Perspectives in Psychiatric Care·Lillian Jan FindlayRif S El-Mallakh

Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome

Feb 24, 2015·Schizophrenia Bulletin·Sanne WulffBirte Yding Glenthøj

Risk of osteoporosis and fracture incidence in patients on antipsychotic medication

Mar 10, 2011·Expert Opinion on Drug Safety·Simon Matthew GrahamEvangelia Tsapakis

Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development

Mar 21, 2015·ACS Chemical Neuroscience·M MöllerB H Harvey

ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers

Apr 7, 2015·Psychopharmacology·Robert E DavisDean F Wong

Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy--a simulation study based on experimental data

Sep 14, 2001·NeuroImage·Hans Olsson, Lars Farde

Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning

Feb 16, 2006·Neuron·Christoph KellendonkEric R Kandel

Error analysis for PET measurement of dopamine D2 receptor occupancy by antipsychotics with [11C]raclopride and [11C]FLB 457

Jul 1, 2008·NeuroImage·Yoko IkomaTetsuya Suhara

Hippocampal Pruning as a New Theory of Schizophrenia Etiopathogenesis

Apr 24, 2015·Molecular Neurobiology·Enrico CocchiAlessandro Serretti

FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol

Jun 19, 2007·Schizophrenia Research·Monte S BuchsbaumErin A Hazlett

A Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics?

May 17, 2013·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Ganesan VenkatasubramanianBangalore N Gangadhar

Central nervous system drug evaluation using positron emission tomography

Apr 1, 2011·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Mizuho SekineTetsuya Suhara

Motivational Context Modulates Prediction Error Response in Schizophrenia

Apr 24, 2016·Schizophrenia Bulletin·Jenna M ReinenDaphna Shohamy

NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis

Mar 23, 2011·Neuropharmacology·Gary GilmourMark Tricklebank

Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia

Jan 8, 2013·Biological Psychiatry·Jong H YoonCameron S Carter

Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925

Sep 16, 2009·The International Journal of Neuropsychopharmacology·Ariel Graff-GuerreroS Kapur

Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas

Apr 16, 2010·The International Journal of Neuropsychopharmacology·Ingo VernalekenGerhard Gründer

PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain

Aug 22, 2007·The International Journal of Neuropsychopharmacology·A L NordströmDavid M Weiner

Disruption of Akt signaling decreases dopamine sensitivity in modulation of inhibitory synaptic transmission in rat prefrontal cortex

May 11, 2016·Neuropharmacology·Yan-Chun LiWen-Jun Gao

Involvement of Basal Ganglia network in motor disabilities induced by typical antipsychotics

Jul 10, 2009·PloS One·Jonathan ChetritAbdelhamid Benazzouz

Neuroreceptor imaging in psychiatry: theory and applications

Nov 18, 2005·International Review of Neurobiology·W Gordon FrankleMarc Laruelle

Positron emission tomography in CNS drug discovery and drug monitoring

Aug 22, 2014·Journal of Medicinal Chemistry·Markus PielFrank Rösch

Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature

Oct 11, 2016·Clinical Pharmacokinetics·William M Greenberg, Leslie Citrome

A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens

Mar 29, 2003·Psychopharmacology·Zhu LiHerbert Y Meltzer

Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment

Apr 8, 2011·Expert Review of Neurotherapeutics·Gary RemingtonGeorge Foussias

Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity

Aug 1, 2009·Expert Opinion on Drug Discovery·Gianluca NucciItalo Poggesi

Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder

May 22, 2010·Expert Opinion on Pharmacotherapy·Andrea FagioliniBenjamin I Goldstein

Diazepam Inhibits Electrically Evoked and Tonic Dopamine Release in the Nucleus Accumbens and Reverses the Effect of Amphetamine

Dec 31, 2016·ACS Chemical Neuroscience·Alexander Gomez-AClaudio Da Cunha

Glutamate and dopamine in schizophrenia: an update for the 21st century

Jan 15, 2015·Journal of Psychopharmacology·Oliver D HowesJames M Stone

Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof

Feb 22, 2013·Journal of Psychopharmacology·Hidenobu SuzukiYuichi Inoue

Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol

Oct 2, 2003·The Annals of Pharmacotherapy·Stanford S JheeSteve J Sims

The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum

Apr 12, 2017·Translational Psychiatry·C T SmithD H Zald

The KCNQ channel activator retigabine blocks haloperidol-induced c-Fos expression in the striatum of the rat

May 26, 2004·Neuroscience Letters·Jens D Mikkelsen

Neuroreceptor imaging studies in schizophrenia

Oct 10, 2007·Harvard Review of Psychiatry·W Gordon Frankle

Guidelines for the use of antipsychotic drug studies in healthy volunteers. The BAP Consensus Group

Jan 1, 1997·Journal of Psychopharmacology·D J King

How to evaluate side effects in a clinical trial?

Feb 27, 2017·L'Encéphale·M MaurelJ-M Azorin

Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients

Mar 1, 2008·Journal of Psychopharmacology·A M CatafauBarcelona Clinical Imaging in Psychiatry Group

Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia

Jan 1, 1997·Journal of Psychopharmacology·G F Busatto, R W Kerwin

D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study

Feb 24, 2001·Journal of Psychopharmacology·E M MeisenzahlH J Möller

Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine

Sep 11, 2004·Journal of Psychopharmacology·Rosa Maria MorescoFerruccio Fazio

Monitoring Haloperidol Plasma Concentration and Associated Adverse Events in Critically Ill Children With Delirium: First Results of a Clinical Protocol Aimed to Monitor Efficacy and Safety

Dec 15, 2017·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Valerie D SlooffSaskia N de Wildt

Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO

Jan 19, 2018·The International Journal of Neuropsychopharmacology·Amane TatenoYoshiro Okubo

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome

Oct 24, 2017·International Journal of Molecular Sciences·Sang Won Jeon, Yong-Ku Kim

Quantitative validation of an intracerebral beta-sensitive microprobe system to determine in vivo drug-induced receptor occupancy using [11C]raclopride in rats

Mar 23, 2004·Synapse·Nathalie GinovartS Kapur

Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine

Mar 23, 2004·Synapse·David C MamoS Kapur

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Aug 4, 2004·Molecular Psychiatry·S MiyamotoJ A Lieberman

Do doctors agree on doses of antipsychotic medications?

Dec 23, 2016·Therapeutic Advances in Psychopharmacology·Johan Schill, Hans Olsson

Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications

Sep 7, 2011·Molecular Psychiatry·T A P LettD J Müller

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

Oct 30, 2013·Molecular Psychiatry·E M P PoelsRagy R Girgis

TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms

Feb 6, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kazunori SuzukiHaruhide Kimura

The role of emission tomography in pharmacokinetic and pharmacodynamic studies in clinical psychopharmacology

Jun 21, 2006·Journal of Psychopharmacology·Andrea L Malizia

TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia

Jan 11, 2018·CNS Neuroscience & Therapeutics·Kazunori Suzuki, Haruhide Kimura

Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis

Jun 23, 2011·Journal of Clinical Psychopharmacology·Hiroyuki UchidaDavid C Mamo

Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride

Jun 23, 2011·Journal of Clinical Psychopharmacology·Jong-Hoon KimZang-Hee Cho

Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine

Jun 2, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert M KesslerHerbert Y Meltzer

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo

Oct 23, 1997·Clinical Pharmacology and Therapeutics·V OzdemirW Kalow

The pipeline and future of drug development in schizophrenia

Aug 2, 2007·Molecular Psychiatry·J A Gray, B L Roth

Polypharmacy with second-generation antipsychotics: a review of evidence

Dec 6, 2008·Journal of Psychiatric Practice·Anand K Pandurangi, Alican Dalkilic

Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry

May 21, 2010·Journal of Psychiatric Practice·Sheldon H Preskorn

How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone

Jun 1, 2010·Journal of Psychiatric Practice·Jana LincolnSheldon H Preskorn

Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone)

Nov 18, 2008·Journal of Clinical Psychopharmacology·Ingo VernalekenGerhard Gründer

Role of basal ganglia neurocircuitry in the pathology of psychiatric disorders

Feb 9, 2019·Psychiatry and Clinical Neurosciences·Tom Macpherson, Takatoshi Hikida

Central muscarinic acetylcholine receptor availability in patients treated with clozapine

Jun 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Thomas J RaedlerDaniel R Weinberger

Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice

Dec 12, 2002·Molecular Psychiatry·R XuY Wang

Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers

Sep 1, 2005·Pharmaceutical Research·Meindert DanhofGilles Paintaud

Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens

Mar 18, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daniel F ManvichDavid Weinshenker

Antipsychotic drug action: targets for drug discovery with neurochemical imaging

Feb 10, 2006·Expert Review of Neurotherapeutics·James M Stone, Lyn S Pilowsky

Dopamine and antipsychotic drug action revisited

Oct 3, 2002·The British Journal of Psychiatry : the Journal of Mental Science·H M Jones, Lyn S Pilowsky

Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele

Aug 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Ross McD YoungErnest P Noble

Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia

Dec 4, 2001·The British Journal of Psychiatry : the Journal of Mental Science·X XiberasM L Paillère-Martinot

In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study

Jan 25, 2000·The British Journal of Psychiatry : the Journal of Mental Science·V BiglianiLyn S Pilowsky

State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics

Feb 28, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·H J Möller

Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis

Aug 21, 2013·Journal of Clinical Psychopharmacology·Irene M LakoKatja Taxis

Allostatic load as a tool for monitoring physiological dysregulations and comorbidities in patients with severe mental illnesses

Nov 10, 2013·Harvard Review of Psychiatry·Gustav BizikRobert-Paul Juster

Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia

Dec 2, 2019·Psychopharmacology·Grant McQueenAlice Egerton

A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia

Dec 18, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ragy R GirgisMark Slifstein

Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale

Oct 12, 2013·Journal of Clinical Psychopharmacology·Venkatesh Pilla ReddyJohannes H Proost

Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients

Aug 5, 1998·Journal of Clinical Psychopharmacology·A L Nordström, Lars Farde

The relationship between risperidone plasma levels and dopamine D2 occupancy: a positron emission tomographic study

Feb 24, 1998·Journal of Clinical Psychopharmacology·G RemingtonR B Zipursky

Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia

Feb 21, 2013·Journal of Clinical Psychopharmacology·Amane TatenoYoshiro Okubo

In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia

Mar 29, 2001·Journal of Clinical Psychopharmacology·X XiberasM L Paillère-Martinot

Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera

Jan 20, 2004·Glia·Tania BordaLeonor Sterin-Borda

A review of a recently published guidelines' "strong recommendation" for therapeutic drug monitoring of olanzapine, haloperidol, perphenazine, and fluphenazine

Jul 12, 2019·The Mental Health Clinician·Christopher Noel

PET technology for drug development in psychiatry

May 29, 2020·Neuropsychopharmacology Reports·Ryosuke ArakawaChrister Halldin

Prediction of response to drug therapy in psychiatric disorders

May 26, 2018·Open Biology·Shani SternFred H Gage

Prediction of Response to Drug Therapy in Psychiatric Disorders

Feb 5, 2020·Focus : Journal of Life Long Learning in Psychiatry·Shani SternFred H Gage

Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges

Jul 29, 2020·Frontiers in Pharmacology·Huixi ZouXiaoyu Yan

Intramuscular olanzapine: a review of its use in the management of acute agitation

Feb 9, 2005·CNS Drugs·Antona J WagstaffLesley J Scott

Glutamatergic hypothesis of schizophrenia

Sep 17, 2003·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Rodrigo A Bressan, Lyn S Pilowsky

Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis

Sep 1, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R B ZipurskyS Kapur

Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18 F]DOPA PET Study

Nov 20, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Euitae KimJun Soo Kwon

Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment

Sep 15, 2020·Therapeutic Advances in Psychopharmacology·Shaina MuscoIan Caudle

Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms

Sep 8, 1998·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R Lewis

Clinical pharmacology of psychotropic drugs

Oct 31, 2002·Human Psychopharmacology·Alain Patat

Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data

Mar 5, 2017·CNS Drugs·Mats O MagnussonAlberto Russu

Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents

Feb 9, 2018·Pharmacology Research & Perspectives·Kazunori SuzukiHaruhide Kimura

Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up

Feb 1, 1997·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Gary RemingtonK Z Bezchlibnyk-Butler

Optimal haloperidol dosage in first-episode psychosis

Mar 31, 1999·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·J Zhang-WongG Bean

Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

Nov 20, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kimberly E VanoverDean F Wong

Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench

Apr 26, 2000·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·S KapurGary Remington

Rational pharmacotherapy in early psychosis

Aug 2, 2005·The British Journal of Psychiatry. Supplement·Gary Remington

Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system

May 5, 2005·Drugs in R&D·Larry Ereshefsky, Erik Mannaert

Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery

Aug 3, 2012·Expert Review of Neurotherapeutics·Andra MihaliInna Gaisler-Salomon

Predicting the dopamine D2 receptor occupancy of ropinirole in rats using positron emission tomography and pharmacokinetic-pharmacodynamic modeling

Jan 16, 2018·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Chenrong HuangLiyan Miao

The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia

Jul 1, 2020·CNS Spectrums·Konstantinos N FountoulakisAfzal Javed

Striatal dopamine D2 receptor occupancy induced by daily application of blonanserin transdermal patches: Phase 2 study in Japanese patients with schizophrenia

Sep 17, 2020·The International Journal of Neuropsychopharmacology·Hironori NishibeYoshiro Okubo

Neuroimaging Biomarkers in Schizophrenia

Jan 6, 2021·The American Journal of Psychiatry·Nina V KraguljacCharles B Nemeroff

Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology

Jul 13, 2019·Neuropharmacology·Stephen J KaarOliver D Howes

PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain

Jan 15, 2021·Cerebral Cortex·Kelly SmartAnsel T Hillmer

Low convergent validity of [11 C]raclopride binding in extrastriatal brain regions: A PET study of within-subject correlations with [11 C]FLB 457

Nov 5, 2020·NeuroImage·Tove FreiburghausSimon Cervenka

Related Concepts

Brain

Double-Blind Method

Factor Construct Rating Scales (Fcrs)

Salicylamides

Schizophrenia

Schizophrenic Psychology

Tomography, Emission-Computed

Antipsychotic Effect

Dopamine D2 Receptor

Raclopride C11

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Synthetic Genetic Array Analysis

Synthetic genetic arrays allow the systematic examination of genetic interactions. Here is the latest research focusing on synthetic genetic arrays and their analyses.

Congenital Hyperinsulinism

Congenital hyperinsulinism is caused by genetic mutations resulting in excess insulin secretion from beta cells of the pancreas. Here is the latest research.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Epigenetic Memory

Epigenetic memory refers to the heritable genetic changes that are not explained by the DNA sequence. Find the latest research on epigenetic memory here.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Femoral Neoplasms

Femoral Neoplasms are bone tumors that arise in the femur. Discover the latest research on femoral neoplasms here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.